Iterum Therapeutics Stock (NASDAQ:ITRM)

Forecast Ownership Financials Chart Transcripts

Previous Close

$0.72

52W Range

$0.66 - $3.02

50D Avg

$0.87

200D Avg

$1.29

Market Cap

$30.51M

Avg Vol (3M)

$781.86K

Beta

2.85

Div Yield

-

ITRM Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance

ITRM Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-18.70M	$-47.47M	$-30.38M
Net Income	$-24.77M	$-38.37M	$-44.43M
EBITDA	$-18.70M	$-34.58M	$-39.97M
Basic EPS	$-1.26	$-2.96	$-3.63
Diluted EPS	$-1.26	$-2.96	$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 05, 25 | 8:30 AM

Q1 25May 13, 25 | 8:30 AM

Q4 24Feb 07, 25 | 8:30 AM

Peer Comparison

Ticker	Company
OTLK	Outlook Therapeutics, Inc.
VISL	Vislink Technologies, Inc.
TNXP	Tonix Pharmaceuticals Holding Corp.
GRCE	Grace Therapeutics, Inc.
TRAW	Traws Pharma, Inc.